Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionRehmann Capital Advisory Group
Latest Disclosed Ownership2,039 shares
Latest Disclosed Value $ 910,495
Rehmann Capital Advisory Group reports 5.27% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 15, 2026 - Rehmann Capital Advisory Group filed a 13F-HR form disclosing ownership of 2,039 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $910,495 USD as of March 31, 2026. The entity filed a previous 13F-HR on March 4, 2026 disclosing 1,937 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 5.27% during the quarter. The current value of the position is $911,086 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,039 102 5.27 910 3.53 0.0474
2026-03-04 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,937 61 3.25 879 19.59 0.0458
2025-11-13 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,876 168 9.84 735 -3.29 0.0403
2025-07-30 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,708 144 9.21 760 0.26 0.0460
2025-04-30 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,564 48 3.17 758 24.26 0.0477
2025-02-14 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,516 -436 -22.34 610 -32.67 0.0387
2024-11-18 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,952 -747 -27.68 906 -28.38 0.0593
2024-08-12 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,699 -81 -2.91 1,265 8.86 0.0906
2024-05-03 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,780 282 11.29 1,162 14.37 0.0866
2024-02-13 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,498 290 13.13 1,016 32.46 0.0842
2023-11-14 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,208 0 0.00 768 -1.29 0.0715
2023-08-23 2023-06-30 13F/A-1 VERTEXPHARMACEUTICALSINC COM 92532F100 2,208 -361 -14.05 777 -3.96 0.0697
2023-08-15 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,569 0 809 0.0761
2023-05-12 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,569 -27 -1.04 809 8.01 0.0761
2023-02-10 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,596 68 2.69 750 2.46 0.0768
2022-11-14 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,528 220 9.53 732 12.46 0.0812
2022-08-12 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,308 -492 -17.57 650 -12.63 0.0716
2022-06-03 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,800 392 16.28 745 40.91 0.0707
2022-03-02 2021-12-31 13F VERTEX PHARMACEUTICALS VRTX 92532F100 2,408 -165 -6.41 529 13.30 0.0492
2021-11-16 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,573 -81 -3.05 466 -7.17 0.0442
2021-08-13 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,654 551 26.20 502 11.31 0.0486
2021-05-26 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,103 279 15.30 451 4.64 0.0461
2021-02-19 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,824 -204 -10.06 431 -21.78 0.0487
2020-11-19 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,028 109 5.68 552 -1.08 0.0700
2020-11-20 2020-06-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 1,919 398 26.17 557 54.29 0.0760
2020-11-20 2020-03-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 1,521 -428 -21.96 362 9.39 0.0591
2020-01-02 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,949 1,509 342.95 330 312.50 0.0399
2019-08-27 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 440 -1 -0.23 81 -1.23 0.0099
2019-05-22 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 441 32 7.82 81 20.90 0.0110
2019-02-12 2018-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 409 75 22.46 68 4.69 0.0102
2018-12-07 2018-09-30 13F/A-1 VERTEXPHARMACEUTICALSINC COM 92532F100 334 -42 -11.17 64 1.59 0.0089
2018-11-20 2018-09-30 13F VERTEXPHARMACEUTICALSINC COM 92532F100 64,375 63,999 0
2018-09-20 2018-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 376 -1,022 -73.10 64 -72.37 0.0093
2018-04-24 2018-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,398 1,398 228 0.0355
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.